Abstract
In the last decade, meningococcal serogroup C conjugate vaccination programs have been demonstrated to be hugely successful with a truly impressive public health impact. In sub-Saharan Africa, with the implementation of an affordable serogroup A conjugate vaccine, it is hoped that a similar public health impact will be demonstrated. Challenges still remain in the quest to develop and implement broadly protective vaccines against serogroup B disease. New, broad coverage vaccines against serogroup B are for the first time becoming available although little is known about their antibody persistence, effectiveness or effect on nasopharyngeal carriage. Enhanced surveillance following any potential vaccine introduction against serogroup B needs to be thoroughly implemented. The future now holds a distinct possibility, globally, for substantially decreasing meningococcal disease, regardless of infecting serogroup.
Original language | English |
---|---|
Pages (from-to) | 1478-1491 |
Number of pages | 14 |
Journal | Tropical Medicine and International Health |
Volume | 17 |
Issue number | 12 |
DOIs | |
Publication status | Published - Dec 2012 |
Bibliographical note
Copyright:Copyright 2014 Elsevier B.V., All rights reserved.
Keywords
- Conjugate
- Meningococcus
- Polysaccharide
- Vaccine